Dr. Laure-Anne Teuwen, a medical oncologist at the University Hospital Antwerpen, shared her thoughts on some interesting abstracts presented during the poster discussion session on GU cancer, specifically kidney and bladder.
The first study she discussed was the phase 2 KEYNOTE-B61 study which tested first-line lenvatinib in combination with pembrolizumab treatment across non-clear cell renal cell carcinomas.
Another study reported on the effectiveness of first-line immunotherapy-based regimens in patients with sarcomatoid and/or rhabdoid metastatic non-clear cell RCC. Additionally, there was PROOF 302, a phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma.
Lastly, Dr. Teuwen discussed the JAVELIN Bladder 100 trial, which reported the long-term safety of avelumab first-line maintenance for advanced urothelial carcinoma. Please enjoy this video.
With the educational support of:
